Efficacy and safety of surufatinib plus toripalimab in treatment-naive, PD-L1-positive, advanced or metastatic non-small-cell lung cancer and previously treated small-cell lung cancer: an open-label, single-arm, multicenter, multi-cohort phase II tri
Surufatinib plus toripalimab showed encouraging antitumor activity and a tolerable safety profile in patients with treatment-naive advanced or metastatic PD-L1-positive NSCLC and previously treated SCLC.
Authors
- Baorui Liu (ORCID: https://orcid.org/0000-0002-2539-7732)
- Zhong Chen (ORCID: https://orcid.org/0000-0002-3618-5073)
- Panfeng Tan
- Dongmei Ji (ORCID: https://orcid.org/0000-0003-0647-0153)
- Ming Lu (ORCID: https://orcid.org/0000-0002-0647-9361)
- Yanqiao Zhang (ORCID: https://orcid.org/0000-0002-6206-8364)
- Si Shi (ORCID: https://orcid.org/0000-0002-6652-0629)
- Lijie Song
- Feng Ye (ORCID: https://orcid.org/0000-0002-9159-7767)
- Xing Zhang (ORCID: https://orcid.org/0000-0003-2665-6940)
- Panpan Zhang (ORCID: https://orcid.org/0000-0002-9633-6208)
- Songhua Fan
- Zhendong Chen (ORCID: https://orcid.org/0000-0002-2035-635X)
- Weiguo Su (ORCID: https://orcid.org/0000-0002-6482-3300)
- Ying Cheng (ORCID: https://orcid.org/0009-0008-8384-2647)
- Michael Shi
Institutions
- Harbin Medical University (CN)
- Sun Yat-sen University (CN)
- Anhui Medical University (CN)
- Peking University (CN)
- First Affiliated Hospital of Xiamen University (CN)
- Fudan University Shanghai Cancer Center (CN)
- Peking University Cancer Hospital (CN)
- Jilin Province Tumor Hospital (CN)
- Third Affiliated Hospital of Harbin Medical University (CN)
- Nanjing Drum Tower Hospital (CN)
- Sun Yat-sen University Cancer Center (CN)
- First Affiliated Hospital of Zhengzhou University (CN)
Publication Details
- Journal
- Cancer Immunology Immunotherapy
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1007/s00262-024-03932-x
- Citations
- 3
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 4.56